摘要
利用试管双倍稀释法及纸片法测定ｌｅｖｏｆｌｏｘａｃｉｎ（ＬＶＬＸ）体外抗菌活性，并与其它１０种药物比较。结果表明ＬＶＬＸ对革兰氏阴性菌具有良好抗菌作用，尤以对痢疾杆菌、伤寒杆菌、变形杆菌、肺炎杆菌、产气杆菌、大肠杆菌作用更为突出，ＭＩＣ５０≤０．０３～０．２８μｇ／ｍｌ，ＭＩＣ９０≤０．０３～１２８μｇ／ｍｌ，抑菌率６０％～１００％；其活性为氧氟沙星的１～４倍，比诺氟沙星、头孢呋辛强，与环丙沙星、庆大霉素及头孢噻肟相当。ＬＶＬＸ抗葡萄球菌活性为所测喹诺酮中最强，与头孢唑林相当，对肺炎球菌、溶血性及草绿色链球菌作用与头孢菌素相当。ＬＶＬＸ有较强抗铜绿假单胞菌活性，ＭＩＣ５０与ＭＩＣ９０分别为０．５与６４μｇ／ｍｌ，与阿米卡星及头孢哌酮相当。ＬＶＬＸ为一广谱高效抗菌药物。
The in vitro antibacterial activity of levofloxacin (LVLX) was examined and compared with those of other 10 antibacterial agents with double broth dilution test and K B disk diffusion test. Results showed that LVLX was a potent and broad spectrum antibacterial compound. The MIC 50 s , MIC 90 s and bacterial susceptible rates of LVLX against Enterobacteriaceae including Shigella spp, Salmonella typhi , Proteus spp, Klebsiella pneumoniae, Enterobacter aerogenes and Escherichia coli , were ≤0.03￣0.25μg/ml, ≤0.03￣128μg/ml and 60%￣100%, respectively, which were 1￣4 folds lower than that of ofloxacin and comparable to those of ciprofloxacin, gentamicin and cefotaxime. LVLX was the most potent fluoroquinolones tested and similiar to cefazolin in anti staphylococcus activity. Streptococcus pneumoniae, S.viridans and S.hemolyticus were highly susceptible to LVLX with MIC 90 s of 1￣8μg/ml. LVLX inhibited 50% of Pseudomonas aeruginosa at a concentration of 0.5μg/ml, which was comparable to amikacin and cefoperazone. Acineto bacter spp. was intermediately susceptible to LVLX. The majority of Streptococcus feacalis were resistant to LVLX.
出处
《中国抗生素杂志》
CAS
CSCD
北大核心
1997年第2期140-145,共6页
Chinese Journal of Antibiotics
